Conventional chemotherapeutic drugs have significant limitations. For example, tumors may
develop resistance, cancers may relapse after treatment, and the drugs may induce …

α-particle-emitting radionuclides are highly cytotoxic and are thus promising candidates for
use in targeted radioimmunotherapy of cancer. Due to their high linear energy transfer (LET) …

Here, we propose tailored lipid liquid-crystalline carriers (cubosomes), which incorporate an
anticancer drug (doxorubicin) and complexed short-lived α-emitter (bismuth-213), as a …

INTRODUCTION: Alpha particles possess an exquisite degree of cytotoxicity when
employed for targeted α-particle therapy (TAT) or radioimmunotherapy (RIT). 212Pb, which …

Over recent decades multiple therapeutic approaches have been explored for improved
management of peritoneally disseminated malignancies—a grim condition known as …

This study reviews the increasing utilization of bismuth in the biomedical field over the past
two decades. Through bibliometric analysis, the research trends including publication …

In spite of development of molecular therapeutics, multiple myeloma (MM) is fatal in most
cases. CD38 is a promising target for selective treatment of MM. We tested …

The approval of 223Ra dichloride (223RaCl2) in 2013 was a principal event in introducing
targeted α-therapy as a form of safe and effective management strategy in cancer. There is …

Apoptosis is involved in aging and age-related disease, with respect to aging, apoptosis
acting in a celltype-specific manner. The rate of apoptosis is elevated in-most types of aging …

Purpose: Ovarian cancer peritoneal metastases (OCPMs) are a pathophysiologically
heterogeneous group of tumors that are rarely curable. αVβ3 integrin (αVβ3) is …